Non-Syndromic X-Linked Intellectual Disability: Research Report

Scope note. Non-syndromic X-linked intellectual disability (NS-XLID) is not one molecularly uniform disease. It is an umbrella category for numerous X-linked neurodevelopmental disorders in which intellectual disability (ID) is the only consistent shared feature. Additional neurologic, behavioral, or dysmorphic findings may occur, but do not form a reproducible syndrome. Consequently, prevalence, penetrance, natural history, biomarkers, and treatment should ideally be curated at the causal-gene/variant level rather than assigned uniformly to the umbrella term. The boundary with syndromic XLID is increasingly regarded as blurred or biologically arbitrary. (tejada2020non‐syndromicxlinked pages 1-5, neri2018x‐linkedintellectualdisability pages 3-4, tejada2020non‐syndromicxlinked pages 12-15)

Executive summary

• Identifier: MONDO:0019181. Open Targets associates this record with 25 targets, including HCFC1, RPS6KA3, ARX, IQSEC2, OGT, BRWD3, IL1RAPL1, AFF2, TSPAN7, SLC9A7, CLCN4, DLG3, GDI1, SYP, HUWE1, and others. This database list is not equivalent to a fully validated contemporary clinical gene panel. (OpenTargets Search: non-syndromic X-linked intellectual disability)
• Definition: ID begins during development and impairs intellectual and adaptive functioning. In NS-XLID, ID is the only common feature across affected individuals; variable speech delay, hypotonia, epilepsy, autistic traits, or minor dysmorphism may coexist. (tejada2020non‐syndromicxlinked pages 1-5)
• Etiology: Rare germline X-chromosomal sequence variants, repeat expansions, copy-number/structural variants, or occasionally mosaic variants disrupt diverse but interconnected neuronal pathways. A 2020 review retained 44 NS-XLID genes after excluding questioned associations; 25 of those also caused syndromic presentations. It reported 56 implicated NS-XLID genes under a broader historical definition and 146 XLID genes overall. (tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 1-5)
• Epidemiology: XLID broadly is estimated to account for approximately 5–10% of ID in males; one 2023 paper cited a prevalence of 1 in 600–1,000 males. These are not reliable prevalence estimates for strict NS-XLID itself, for which no robust population prevalence or incidence was identified. (luca2020challengesinmolecular pages 1-2, mir2023wholeexomesequencing pages 1-2)
• Diagnosis: Clinical assessment, three-generation pedigree, Fragile X testing where indicated, copy-number analysis, and preferably trio exome or genome sequencing with segregation and phenotype-aware reinterpretation. RNA or biochemical assays can resolve selected variants. (luca2020challengesinmolecular pages 1-2, ibarluzea2020targetednextgenerationsequencing pages 1-3)
• Treatment: No disease-group-level disease-modifying treatment is established. Current implementation is genotype-informed surveillance plus developmental, educational, speech-language, occupational, physical, behavioral, psychiatric, and seizure care. Gene therapy, controlled X-reactivation, and synapse/circuit-directed interventions remain experimental. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10, martinez2024overcominggeneticand pages 6-7)

The following ontology-ready summary complements the narrative report.

Table: This table provides a compact, ontology-ready summary of nonsyndromic X-linked intellectual disability for knowledge-base use. It emphasizes heterogeneous gene-dependent biology and highlights that intellectual disability is the only consistent shared feature across the disease group.

1. Disease information

Definition and identifiers

NS-XLID—also called non-specific XLID, nonsyndromal XLID, or historically X-linked nonsyndromic mental retardation—is an early-onset genetic neurodevelopmental disease group. “Non-syndromic” does not mean that every patient has isolated ID; it means no additional feature is consistently shared across the relevant family or disorder definition. The dedicated review states: “Non-Specific or Non-Syndromic Intellectual Disability (NS-XLID) [is that] where the only common feature is ID.” (tejada2020non‐syndromicxlinked pages 1-5)

• MONDO: MONDO:0019181.
• OMIM: No single umbrella OMIM phenotype number was established in the retrieved evidence. Historically, pedigrees were assigned MRX/IDX locus numbers; the 2018 update described 105 nonsyndromal families with IDX numbers, 67 with cloned genes, 33 mapped but unresolved, and five reserved numbers. Individual causal genes and phenotypes have separate OMIM records. (neri2018x‐linkedintellectualdisability pages 3-4)
• Orphanet, MeSH, ICD-10/ICD-11: No unique, validated NS-XLID-specific code was established from the retrieved literature. Clinical coding usually uses intellectual-developmental-disorder and/or genetic-etiology codes, while the molecular diagnosis is recorded separately. These mappings should be verified directly against the current releases before production use.
• Data provenance: The report is principally aggregated disease-level evidence from reviews, databases, family studies, and experimental papers—not individual EHR data. Patient counts are stated where primary cohorts were available.

The historical syndromic/non-syndromic division is unstable: different variants in one gene—and sometimes the same familial variant—can produce either label because of variant location, dosage, genetic background, X-inactivation, and other modifiers. (tejada2020non‐syndromicxlinked pages 1-5, tejada2020non‐syndromicxlinked pages 12-15)

2. Etiology, risk, protection, and gene–environment interaction

Causal factors

The primary cause is a germline pathogenic or likely pathogenic X-chromosomal variant. Relevant classes include missense, nonsense, frameshift, splice-altering, repeat-expansion, exon/gene deletion or duplication, and larger structural variants. Pathogenic mechanisms include loss of function, altered dosage, impaired protein interactions, and occasional apparent gain of function. Most variants are constitutionally inherited or de novo; somatic/gonadal mosaicism is possible but not quantified for the umbrella disease.

Representative clinically supported genes include AFF2, ARX, ATRX, BRWD3, CLCN4, DLG3, FTSJ1, GDI1, HCFC1, HUWE1, IL1RAPL1, IQSEC2, KDM5C, MECP2, MED12, NLGN3, NLGN4X, OGT, OPHN1, PAK3, RAB39B, RPS6KA3, SLC6A8, SLC9A7, SYP, SYN1, TSPAN7, UPF3B, and ZNF711. Gene validity and the “non-syndromic” designation require periodic reassessment; older candidate lists contained associations later questioned by population sequencing. (OpenTargets Search: non-syndromic X-linked intellectual disability, tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 1-5)

A recent human example is the October 2023 WES study of nine affected males from four Iranian families. It identified likely pathogenic ZDHHC9 c.566T>C (p.Leu189Pro), GLRA2 c.1048C>T (p.Arg350Cys), ATP2B3 c.2541C>G (p.Asp847Glu) and previously reported pathogenic L1CAM c.925G>A (p.Glu309Lys) variants. The three novel variants were classified under ACMG/AMP criteria and segregated in X-linked pedigrees. [BMC Medical Genomics, October 2023, DOI: https://doi.org/10.1186/s12920-023-01680-y]. (mir2023wholeexomesequencing pages 1-2, mir2023fourfamilieswith pages 9-11, mir2023wholeexomesequencing pages 4-6)

Risk factors

• Genetic: male hemizygosity; a carrier mother; affected maternal male relatives; a known familial pathogenic variant; X-chromosome structural rearrangement; or de novo mutation.
• Female expression: skewed X-chromosome inactivation (XCI), escape from XCI, dosage sensitivity, mosaicism, and variant mechanism influence risk and severity. Approximately 15–30% of X-linked genes can escape XCI, depending on tissue and cell type. (martinez2024overcominggeneticand pages 1-2)
• Family history: absence of family history does not exclude XLID because de novo variants, small families, reduced female expression, and mosaicism are common diagnostic complications. (luca2020challengesinmolecular pages 1-2)
• Environmental/lifestyle/infectious: no environmental exposure, lifestyle behavior, toxin, or pathogen is a primary cause of monogenic NS-XLID. General prenatal/perinatal insults remain differential causes of ID, not established causes of genetically confirmed NS-XLID.

Protective factors and gene–environment interaction

No reproducible protective allele, diet, lifestyle, medication, or environmental exposure has been established for NS-XLID as a group. Favorable XCI that preferentially silences the mutant allele may reduce expression in heterozygous females, but is tissue-specific and is better considered a modifier than a dependable protective factor. The literature suggests environmental or genetic background can modify phenotype even within a family, but no validated quantitative gene–environment interaction was identified. (tejada2020non‐syndromicxlinked pages 1-5)

3. Phenotypes

Defining phenotype: developmental-onset impairment of intellectual and adaptive functioning (HP:0001249 Intellectual disability), ranging from mild to profound. Developmental delay (HP:0001263) may be recognized before formal cognitive testing. Onset is congenital/developmental, generally becoming apparent in infancy or childhood; the cognitive disability is chronic and lifelong rather than episodic. (tejada2020non‐syndromicxlinked pages 1-5)

Common but non-universal, gene-dependent findings include:

• speech/language delay (HP:0000750), poor or absent speech;
• hypotonia (HP:0001252) and occasionally muscle weakness (HP:0001324);
• seizures/epilepsy (HP:0001250);
• autism (HP:0000729), behavioral abnormality (HP:0000708), or psychiatric symptoms;
• motor delay, variable reflexes, minor dysmorphism, clinodactyly, micro- or macrocephaly, and occasional structural brain anomalies.

These features cannot be assigned meaningful umbrella-level percentages. For example, early IQSEC2 families showed moderate-to-severe ID, while seizures, autistic traits, and psychiatric problems were inconsistent. More than 70 IQSEC2 variants had been reported by 2020, with severe truncating variants often producing a broader encephalopathy. (tejada2020non‐syndromicxlinked pages 12-15)

In the 2023 Iranian series, severe ID, developmental and speech delay were prominent; seizures, behavioral problems, muscle weakness, dysmorphism, agenesis of the corpus callosum, and colpocephaly varied by family and gene. (mir2023wholeexomesequencing pages 2-4, mir2023fourfamilieswith pages 9-11, mir2023wholeexomesequencing pages 4-6)

Quality of life: impairment chiefly affects communication, education, independent living, employment, social participation, and lifelong caregiver needs. Epilepsy, behavioral disorders, and absent speech add substantial morbidity. No NS-XLID-specific EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life estimate was found; quantitative quality-of-life claims should therefore not be imputed from general ID cohorts.

4. Genetic and molecular information

Variant interpretation

Pathogenic variants are generally rare or absent from population databases and evaluated with ACMG/AMP criteria, segregation, phenotype consistency, XCI/escape status, and functional evidence. Healthy carrier mothers do not automatically refute pathogenicity. Conversely, rarity and in-silico prediction alone do not establish causality. RNA sequencing, biochemical assays, deep mutational scanning, and cell models can reclassify variants of uncertain significance. (luca2020challengesinmolecular pages 1-2, ibarluzea2020targetednextgenerationsequencing pages 1-3)

The variant classes and consequences are gene-specific:

• Loss of function: truncating/splice/deletion variants in numerous genes; disturbed synaptic, transcriptional, or transport functions.
• Dosage change: duplications of XLID genes can produce variable phenotypes; excessive expression may be as harmful as deficiency. (tejada2020non‐syndromicxlinked pages 5-8, martinez2024overcominggeneticand pages 6-7)
• Missense/domain effects: IQSEC2 variants in IQ or Sec7 domains can respectively impair calmodulin binding/increase GEF activity or reduce ARF6 GEF activity. (tejada2020non‐syndromicxlinked pages 12-15, tejada2020non‐syndromicxlinked pages 19-23)
• Gain-of-function-like physiology: SLC9A7 p.Leu515Phe causes alkalinization of trans-Golgi/post-Golgi compartments with abnormal glycosylation, despite broadly preserved localization and trafficking. (khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 8-9)

Allele frequency must be documented per exact HGVS allele and genome build in gnomAD; there is no meaningful group-level allele frequency. Germline inheritance predominates. Somatic origin is not a defining feature, although mosaicism should be considered. No consistently validated modifier gene or anticipation phenomenon was found. Founder effects and carrier frequencies are variant/population-specific and not established for the umbrella entity.

X-inactivation and epigenetics

Random XCI creates cellular mosaics in females; escape from XCI and tissue-specific skewing complicate penetrance and blood-to-brain inference. In a 2023 study of 194 women with idiopathic ID, 136 were informative for the androgen-receptor methylation assay; 11/136 (8%) had extreme/total skewing of at least 90%. WES diagnosed 8/11 (73%), including X-linked DDX3X, WDR45, PDHA1 and autosomal KCNB1, CTNNB1, YY1, ANKRD11 variants. Thus extreme XCI is an enrichment signal, not a standalone NS-XLID diagnostic criterion. [Molecular Neurobiology, March 2023, DOI: https://doi.org/10.1007/s12035-023-03311-0]. (chaves2023skewedxchromosomeinactivation pages 1-5)

5. Environmental information

No toxin, radiation exposure, pollutant, occupation, smoking, alcohol pattern, diet, exercise level, or infectious agent is known to cause genetically defined NS-XLID. These factors may influence general neurodevelopment, health, or seizure control, but evidence for a disease-specific causal interaction is absent. NS-XLID is neither infectious nor transmissible, and vaccination is not etiologic or preventive.

6. Mechanism and pathophysiology

The upstream event is a pathogenic X-linked variant. The downstream chain depends on the gene, but several convergent modules emerge:

1. Synaptic vesicle cycling and neurotransmitter release. GDI1 regulates Rab GTPases; IL1RAPL1 regulates calcium-dependent secretion; SYN1 and SYP control synaptic-vesicle trafficking/endocytosis. Defects impair presynaptic release and activity-dependent plasticity. Suggested GO terms: GO:0007268 chemical synaptic transmission, GO:0016079 synaptic vesicle exocytosis. (tejada2020non‐syndromicxlinked pages 8-12)
2. Postsynaptic organization and receptor trafficking. DLG3 organizes NMDA-receptor signaling; GRIA3 encodes an AMPA-receptor component; IQSEC2/ARF6 regulates AMPA trafficking and dendritic actin. Disrupted receptor localization and spine plasticity impair learning and memory. Suggested GO: GO:0048167 regulation of synaptic plasticity, GO:0032956 regulation of actin cytoskeleton organization. (tejada2020non‐syndromicxlinked pages 12-15, tejada2020non‐syndromicxlinked pages 8-12)
3. Chromatin/transcription/RNA regulation. ATRX, MECP2, KDM5C, HCFC1, MED12, UPF3B and related proteins alter chromatin organization, RNA-polymerase-II signaling, splicing, export, translation, or nonsense-mediated decay, disturbing developmental neuronal gene programs. MED12 defects can disrupt GLI3-dependent Sonic Hedgehog, REST-dependent epigenetic signaling, and immediate-early-gene expression. Suggested GO: GO:0006338 chromatin remodeling, GO:0006357 regulation of transcription by RNA polymerase II, GO:0000184 nonsense-mediated mRNA decay. (tejada2020non‐syndromicxlinked pages 5-8, tejada2020non‐syndromicxlinked pages 19-23)
4. Ubiquitin/proteostasis pathways. HUWE1 and other ubiquitin-system genes alter substrate turnover, neuronal proliferation, differentiation, and stress responses. Suggested GO: GO:0016567 protein ubiquitination. (tejada2020non‐syndromicxlinked pages 19-23)
5. Transport, metabolism, and organelles. SLC6A8 deficiency impairs brain creatine uptake and energy buffering; CLCN4 alters endosomal ion homeostasis; NDUFA1/SLC25A5 affect mitochondrial function; SLC9A7 alters Golgi pH and glycosylation. (tejada2020non‐syndromicxlinked pages 12-15, tejada2020non‐syndromicxlinked pages 25-28, khayat2019arecurrentmissense pages 3-4)

Mechanistic exemplar: SLC9A7-related NS-XLID

Khayat and colleagues reported the recurrent SLC9A7 c.1543C>T (p.Leu515Phe) allele in two unrelated families: four Australian males aged 65, 58, 56, and 27 years and two American males aged 36 and four years. Clinical findings included moderate-to-severe ID, speech delay, hypotonia/muscle weakness, reserved personality, variable reflexes, and bilateral clinodactyly; carrier females were clinically unaffected. [Human Molecular Genetics, October 2019; PMID 30335141; DOI: https://doi.org/10.1093/hmg/ddy371]. (khayat2019arecurrentmissense pages 3-4, khayat2019arecurrentmissense pages 45-45)

SLC9A7/NHE7 normally localizes predominantly to the trans-Golgi network (TGN) and post-Golgi vesicles. The mutant retained localization and had a nonsignificantly shorter half-life—2.2 ± 0.43 versus 2.92 ± 1.52 hours—but alkalinized TGN/post-Golgi compartments, impaired N-linked oligosaccharide maturation, and produced abnormal serum-transferrin N-glycosylation. The causal chain is therefore: missense variant → dysregulated organellar proton/cation exchange → Golgi alkalinization → abnormal cargo glycosylation → altered neuronal protein processing → neurodevelopmental impairment. Evidence is human genetic plus serum biochemical and transfected-cell functional evidence, not yet proof of every downstream brain step. (khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 8-9)

Cells, anatomy, immune/tissue injury, and omics

Relevant cells are principally neurons—especially cortical and hippocampal excitatory and inhibitory populations—and their synapses; glia may participate in selected disorders. Suggested terms include CL:0000540 neuron, plus release-verified cortical, glutamatergic, GABAergic, and hippocampal neuronal subclasses. The primary organ is the brain (UBERON:0000955), particularly cerebral cortex (UBERON:0000956) and distributed cognitive circuits. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 11-12, martinez2024overcominggeneticand pages 1-2)

There is no common autoimmune, immunodeficiency, inflammatory, ischemic, fibrotic, necrotic, or oxidative-tissue-injury mechanism for NS-XLID as a whole. Likewise, no validated umbrella-level transcriptomic, proteomic, metabolomic, or lipidomic diagnostic signature exists. Gene-specific data include transferrin glycosylation in SLC9A7 and creatine abnormalities in SLC6A8. Single-cell, spatial-transcriptomic, and integrated multi-omic findings remain research-stage and are not sufficiently uniform for disease-group annotation.

7. Anatomical structures affected

• Primary system: central nervous system.
• Organ/site: brain and distributed bilateral neural circuits; no characteristic lateralization.
• Tissue: nervous tissue, especially cortical and hippocampal networks.
• Cellular: neurons, dendrites, axons, synapses; gene-dependent involvement of glia is possible.
• Subcellular: synaptic vesicle, presynapse, postsynaptic density, dendritic spine, nucleus/chromatin, Golgi/TGN, endosome, or mitochondrion according to gene. Suggested GO cellular-component terms include GO:0045202 synapse, GO:0014069 postsynaptic density, GO:0043197 dendritic spine, GO:0005794 Golgi apparatus, GO:0005802 TGN, GO:0005768 endosome, GO:0005739 mitochondrion. (tejada2020non‐syndromicxlinked pages 23-25, tejada2020non‐syndromicxlinked pages 25-28, tejada2020non‐syndromicxlinked pages 8-12, khayat2019arecurrentmissense pages 3-4)

Secondary organ involvement is not intrinsic to strict NS-XLID. Consistent extracerebral abnormalities should prompt reconsideration of a gene-specific syndromic diagnosis.

8. Temporal development

Onset is developmental, usually recognized through delayed milestones, language delay, learning difficulty, or adaptive impairment in infancy or childhood. ID is chronic and lifelong. The core cognitive deficit is usually relatively stable rather than relapsing-remitting, although developmental gains occur and comorbid epilepsy or behavior may fluctuate. There is no accepted staging system, remission pattern, or end stage for the umbrella disease.

Early childhood is the key period for diagnostic testing and developmental intervention because neuroplasticity and acquisition of communication/adaptive skills are greatest. Evidence does not support spontaneous cure. Gene-specific disorders may be progressive or epileptic-encephalopathic and should not be generalized to strict NS-XLID.

9. Inheritance and population

Inheritance is usually X-linked: hemizygous males are more frequently and often more severely affected, while heterozygous females range from unaffected to severely affected depending on XCI, escape, dosage, and variant mechanism. Some genes behave as X-linked dominant disorders with frequent de novo female cases rather than conventional recessive traits. (luca2020challengesinmolecular pages 1-2, martinez2024overcominggeneticand pages 1-2, chaves2023skewedxchromosomeinactivation pages 1-5)

ID overall is reported around 1%, with male prevalence approximately 30% higher than female prevalence in one meta-analytic summary. XLID mutations account for an estimated 5–10% of male ID, but strict NS-XLID prevalence, incidence, carrier frequency, geographic distribution, and male:female ratio are unavailable. (tejada2020non‐syndromicxlinked pages 1-5, luca2020challengesinmolecular pages 1-2)

Penetrance and expressivity are gene- and sex-dependent. Germline mosaicism is relevant for counseling after an apparently de novo result, but no umbrella recurrence percentage is available. Genetic anticipation is not characteristic, except that AFF2/FMR2- and FMR1-related repeat biology must be handled under their specific disease definitions. Consanguinity is not a primary risk factor for X-linked disease, although it can clarify or complicate pedigrees. Founder alleles and population differences must be assessed variant by variant; the 2023 Iranian family study illustrates the importance of studying underrepresented ancestries but does not establish a general regional excess. (mir2023wholeexomesequencing pages 1-2, mir2023wholeexomesequencing pages 4-6)

10. Diagnostics

Recommended workflow

1. Confirm developmental ID using standardized cognitive and adaptive-behavior assessment; document neurologic, behavioral, growth, dysmorphic, and systemic findings.
2. Obtain prenatal/perinatal history and a three-generation pedigree, specifically maternal male relatives and mildly affected females.
3. Perform hearing/vision assessment and phenotype-directed EEG, brain MRI, metabolic tests, or biochemical assays. EEG and MRI are not universal diagnostic biomarkers.
4. Test FMR1 CGG expansion when clinically/family-history indicated. Standard exome sequencing does not reliably exclude repeat expansion.
5. Use trio exome sequencing or genome sequencing early, with validated CNV calling. Chromosomal microarray remains useful where sequencing-based CNV detection is unavailable or structural variation is suspected.
6. Analyze a curated ID/XLID gene set but do not restrict interpretation to X-linked genes; apparent XLID pedigrees can have autosomal or de novo causes.
7. Confirm relevant variants orthogonally where required; perform parental/segregation testing, ACMG/AMP classification, and periodic reanalysis.
8. Add RNA studies, methylation/XCI studies, enzyme/transporter assays, metabolomics, or glycosylation testing when a candidate mechanism warrants it. (luca2020challengesinmolecular pages 1-2, ibarluzea2020targetednextgenerationsequencing pages 1-3, chaves2023skewedxchromosomeinactivation pages 1-5)

In a panel study of 61 unrelated males with suggestive NS-XLID after normal karyotype and FMR1 testing, sequencing 82 XLID genes found 17 candidate variants in 16 patients. The authors cited approximately 25% diagnostic yields for panel/X-exome strategies and stressed segregation, RNA, and biochemical follow-up. [Genes, January 2020, DOI: https://doi.org/10.3390/genes11010051]. (ibarluzea2020targetednextgenerationsequencing pages 1-3)

Gene-specific adjuncts include elevated urine creatine/creatinine and reduced brain creatine by proton MRS for SLC6A8 deficiency, and serum-transferrin N-glycosylation for SLC9A7. These are not universal NS-XLID biomarkers. (tejada2020non‐syndromicxlinked pages 12-15, khayat2019arecurrentmissense pages 2-3)

Differential diagnosis and screening

Differentials include Fragile X syndrome, syndromic XLID, autosomal dominant/recessive ID, chromosomal CNVs, mitochondrial disease, cerebral palsy, fetal alcohol exposure, congenital infection, endocrine/metabolic disorders, autism without ID, and acquired brain injury. There are no universal NS-XLID clinical criteria beyond developmental ID plus a confirmed causal X-linked diagnosis and absence of a consistent defining syndrome.

No population newborn screen exists. Appropriate screening comprises cascade testing after a familial diagnosis, targeted carrier testing, and variant-specific prenatal/preimplantation testing. Broad carrier screening may not capture all genes/variant classes.

11. Outcome and prognosis

No NS-XLID-specific survival curves, mortality rates, or life-expectancy estimates were identified. Isolated cognitive disability is not inherently life-limiting, but prognosis varies with epilepsy, aspiration, mobility, congenital anomalies, or gene-specific systemic disease. Functional morbidity is lifelong and may include dependence in communication, education, employment, finances, and daily living.

Recovery to typical cognition is not expected, although developmental, educational, and communication gains can be substantial. Prognostic factors are causal gene/variant, severity of early delay, epilepsy burden, speech acquisition, motor ability, behavior, and access to intervention. No validated molecular prognostic biomarker applies across NS-XLID.

12. Treatment and current applications

There is no FDA/EMA-approved pharmacotherapy, surgery, cell therapy, immunotherapy, RNA therapy, or gene therapy for NS-XLID as an umbrella disease. Current real-world management is multidisciplinary:

• early intervention and individualized education;
• speech-language therapy, including augmentative/alternative communication;
• occupational and physical therapy;
• behavioral and psychiatric assessment/intervention;
• standard genotype- and seizure-type-appropriate antiseizure medication;
• treatment of sleep, feeding, gastrointestinal, sensory, orthopedic, or other comorbidities;
• social-work support, respite care, transition planning, and supported decision-making.

Suggested NCIT intervention concepts, with current-release verification, are Supportive Care, Speech Therapy, Occupational Therapy, Physical Therapy, Behavioral Therapy, Genetic Counseling, Anticonvulsant Therapy, Whole Exome Sequencing, and Gene Therapy.

A ClinicalTrials.gov search did not identify a disease-modifying interventional trial for strict NS-XLID. Relevant research infrastructure includes NCT02854956, a broad XLID clinical phenotyping/neural-network study, and NCT06500260, an observational CNKSR2 natural-history study. Trials for Fragile X, Rett, or CDKL5-related disease should not be represented as treatments for NS-XLID.

Experimental directions include AAV gene replacement, dosage-controlled transgenes, RNA destabilization/microRNA regulatory elements, and selective reactivation of the healthy inactive X chromosome. Experts emphasize that mosaic females create a central safety problem: indiscriminate expression may rescue mutant cells while overdosing cells already expressing the normal allele. CRISPR/pharmacologic X-reactivation currently lacks adequate cellular specificity. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10, martinez2024overcominggeneticand pages 6-7)

13. Prevention

Primary prevention through lifestyle modification, vaccination, or environmental avoidance is not applicable to a monogenic disease group. Actionable prevention is reproductive and family-based:

• genetic counseling and precise variant interpretation;
• cascade testing of at-risk relatives;
• carrier testing with discussion of variable female expression;
• prenatal diagnosis by chorionic-villus sampling or amniocentesis for a known familial variant;
• preimplantation genetic testing for monogenic disease;
• counseling about residual recurrence risk from gonadal mosaicism;
• early developmental surveillance of at-risk or diagnosed children.

Secondary/tertiary prevention consists of early diagnosis, timely therapy, seizure recognition, safety planning, and prevention of avoidable complications. There is no prophylactic drug or immunization specific to NS-XLID. (luca2020challengesinmolecular pages 1-2, mir2023wholeexomesequencing pages 1-2)

14. Other species and natural disease

No naturally occurring veterinary disease corresponding to the aggregate human NS-XLID category was identified. The condition is not infectious, zoonotic, or cross-species transmissible. Orthologous genes are widely conserved in mammals and other vertebrates, but NCBI Gene/Taxonomy identifiers must be attached gene by gene rather than to the umbrella disease. Relevant experimental species include Homo sapiens (NCBI Taxon 9606) and Mus musculus (10090); zebrafish, Drosophila, and cultured mammalian cells are also plausible gene-specific systems. No VBO breed association is applicable at group level.

15. Model organisms and advanced technologies

Model choice is gene-specific. Available approaches include knockout, knock-in, conditional, reporter, and mosaic mice; transfected mammalian cells; patient-derived fibroblasts; human iPSCs and differentiated neurons; and, for selected genes, zebrafish or invertebrate models.

The 2024 expert review highlights a major limitation: conventional hemizygous knockout mice do not reproduce the cellular mosaicism of heterozygous human females. Proposed F1 crosses combine X-linked reporters with mutant alleles so wild-type and mutant cells can be distinguished while retaining random XCI. dual-eGRASP, split-biotin-ligase systems, electrophysiology, calcium/voltage imaging, optogenetics, and chemogenetics can then resolve cell-type-specific synaptic and circuit defects. [Journal of Neurodevelopmental Disorders, February 2024, DOI: https://doi.org/10.1186/s11689-024-09517-0]. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 8-10)

Evidence from broader X-linked neurodevelopmental models includes abnormal allele-specific neuronal clustering and circuit development in mosaic PCDH19 models, altered callosal/hippocampal NMDA-receptor circuitry in CDKL5 models, patient-derived CDKL5 iPSCs, and experimental rescue of dendritic-spine instability with IGF-1. These are mechanistically informative but are not direct treatment evidence for strict NS-XLID. (martinez2024overcominggeneticand pages 6-7, martinez2024overcominggeneticand pages 11-12)

Key limitations and knowledge gaps

1. The nonsyndromic/syndromic dichotomy is unstable, and gene counts vary with curation criteria.
2. Most phenotype frequencies, prognoses, and biomarkers are gene-specific; aggregate percentages would be misleading.
3. Blood XCI may not represent brain XCI.
4. Many mechanistic conclusions rely on cells or animals rather than direct human neural tissue.
5. NS-XLID-specific natural-history cohorts, patient-reported outcomes, single-cell/spatial atlases, and therapeutic trials remain scarce.
6. OMIM, Orphanet, ICD, MeSH, HGNC, HPO, GO, CL, UBERON, LOINC, CHEBI, and NCIT mappings should be release-verified before database ingestion.

Selected authoritative sources

• Tejada MI, Ibarluzea N. Non-syndromic X-linked intellectual disability: current knowledge in light of recent molecular and functional studies. Clinical Genetics. Published January 2020. DOI: https://doi.org/10.1111/cge.13698. Abstract statement: “the only common feature is ID,” while distinct variants in several genes can cause syndromic or nonsyndromic disease. (tejada2020non‐syndromicxlinked pages 1-5)
• Neri G, Schwartz CE, Lubs HA, Stevenson RE. X-linked intellectual disability update 2017. American Journal of Medical Genetics A. Published June 2018. DOI: https://doi.org/10.1002/ajmg.a.38710. (neri2018x‐linkedintellectualdisability pages 3-4, neri2018x‐linkedintellectualdisability pages 1-3)
• Mir A et al. Whole exome sequencing revealed variants in four genes underlying XLID in four Iranian families. BMC Medical Genomics. Published October 2023. DOI: https://doi.org/10.1186/s12920-023-01680-y. (mir2023wholeexomesequencing pages 1-2, mir2023wholeexomesequencing pages 4-6)
• Chaves LD et al. Skewed X-chromosome inactivation in women with idiopathic ID is indicative of pathogenic variants. Molecular Neurobiology. Published March 2023. DOI: https://doi.org/10.1007/s12035-023-03311-0. (chaves2023skewedxchromosomeinactivation pages 1-5)
• Martinez D, Jiang E, Zhou Z. Overcoming genetic and cellular complexity to study the pathophysiology of XLIDs. Journal of Neurodevelopmental Disorders. Published February 2024. DOI: https://doi.org/10.1186/s11689-024-09517-0. (martinez2024overcominggeneticand pages 7-8, martinez2024overcominggeneticand pages 1-2)
• Khayat W et al. A recurrent missense variant in SLC9A7 causes nonsyndromic XLID with alteration of Golgi acidification and aberrant glycosylation. Human Molecular Genetics. Published October 2019; PMID: 30335141. DOI: https://doi.org/10.1093/hmg/ddy371. Abstract-supported statement: patient serum showed “an abnormal N-glycosylation profile for transferrin,” implicating TGN/post-Golgi pH homeostasis and cargo glycosylation. (khayat2019arecurrentmissense pages 2-3, khayat2019arecurrentmissense pages 45-45)
• De Luca C et al. Challenges in molecular diagnosis of X-linked intellectual disability. British Medical Bulletin. Published February 2020. DOI: https://doi.org/10.1093/bmb/ldz039. (luca2020challengesinmolecular pages 1-2)
• Ibarluzea N et al. Targeted next-generation sequencing in patients with suggestive XLID. Genes. Published January 2020. DOI: https://doi.org/10.3390/genes11010051. (ibarluzea2020targetednextgenerationsequencing pages 1-3)

References

1. (tejada2020non‐syndromicxlinked pages 1-5): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

2. (neri2018x‐linkedintellectualdisability pages 3-4): Giovanni Neri, Charles E. Schwartz, Herbert A. Lubs, and Roger E. Stevenson. X‐linked intellectual disability update 2017. American Journal of Medical Genetics Part A, 176:1375-1388, Jun 2018. URL: https://doi.org/10.1002/ajmg.a.38710, doi:10.1002/ajmg.a.38710. This article has 154 citations.

3. (tejada2020non‐syndromicxlinked pages 12-15): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

4. (OpenTargets Search: non-syndromic X-linked intellectual disability): Open Targets Query (non-syndromic X-linked intellectual disability, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

5. (tejada2020non‐syndromicxlinked pages 23-25): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

6. (luca2020challengesinmolecular pages 1-2): Chiara De Luca, Valérie Race, Liesbeth Keldermans, Marijke Bauters, and Hilde Van Esch. Challenges in molecular diagnosis of x-linked intellectual disability. British medical bulletin, Feb 2020. URL: https://doi.org/10.1093/bmb/ldz039, doi:10.1093/bmb/ldz039. This article has 36 citations and is from a peer-reviewed journal.

7. (mir2023wholeexomesequencing pages 1-2): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad Amin Tabatabaiefar. Whole exome sequencing revealed variants in four genes underlying x-linked intellectual disability in four iranian families: novel deleterious variants and clinical features with the review of literature. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01680-y, doi:10.1186/s12920-023-01680-y. This article has 10 citations and is from a peer-reviewed journal.

8. (ibarluzea2020targetednextgenerationsequencing pages 1-3): Nekane Ibarluzea, Ana Belén de la Hoz, Olatz Villate, Isabel Llano, Intzane Ocio, Itxaso Martí, Miriam Guitart, Elisabeth Gabau, Fernando Andrade, Blanca Gener, and María-Isabel Tejada. Targeted next-generation sequencing in patients with suggestive x-linked intellectual disability. Genes, 11:51, Jan 2020. URL: https://doi.org/10.3390/genes11010051, doi:10.3390/genes11010051. This article has 34 citations.

9. (martinez2024overcominggeneticand pages 7-8): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.

10. (martinez2024overcominggeneticand pages 8-10): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.

11. (martinez2024overcominggeneticand pages 6-7): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.

12. (khayat2019arecurrentmissense pages 3-4): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.

13. (mir2023wholeexomesequencing pages 2-4): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad Amin Tabatabaiefar. Whole exome sequencing revealed variants in four genes underlying x-linked intellectual disability in four iranian families: novel deleterious variants and clinical features with the review of literature. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01680-y, doi:10.1186/s12920-023-01680-y. This article has 10 citations and is from a peer-reviewed journal.

14. (mir2023fourfamilieswith pages 9-11): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad-Amin Tabatabaiefar. Four families with x-linked intellectual disability affected males: novel deleterious variants and clinical features with the review of literature. Unknown journal, Apr 2023. URL: https://doi.org/10.21203/rs.3.rs-2833503/v1, doi:10.21203/rs.3.rs-2833503/v1.

15. (mir2023wholeexomesequencing pages 4-6): Atefeh Mir, Yongjun Song, Hane Lee, Hossein Khanahmad, Erfan Khorram, Jafar Nasiri, and Mohammad Amin Tabatabaiefar. Whole exome sequencing revealed variants in four genes underlying x-linked intellectual disability in four iranian families: novel deleterious variants and clinical features with the review of literature. BMC Medical Genomics, Oct 2023. URL: https://doi.org/10.1186/s12920-023-01680-y, doi:10.1186/s12920-023-01680-y. This article has 10 citations and is from a peer-reviewed journal.

16. (tejada2020non‐syndromicxlinked pages 19-23): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

17. (tejada2020non‐syndromicxlinked pages 5-8): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

18. (tejada2020non‐syndromicxlinked pages 8-12): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

19. (martinez2024overcominggeneticand pages 1-2): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.

20. (martinez2024overcominggeneticand pages 11-12): Dayne Martinez, Evan Jiang, and Zhaolan Zhou. Overcoming genetic and cellular complexity to study the pathophysiology of x-linked intellectual disabilities. Journal of Neurodevelopmental Disorders, Feb 2024. URL: https://doi.org/10.1186/s11689-024-09517-0, doi:10.1186/s11689-024-09517-0. This article has 9 citations and is from a peer-reviewed journal.

21. (khayat2019arecurrentmissense pages 2-3): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.

22. (khayat2019arecurrentmissense pages 8-9): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.

23. (tejada2020non‐syndromicxlinked pages 25-28): María Isabel Tejada and Nekane Ibarluzea. Non‐syndromic x linked intellectual disability: current knowledge in light of the recent advances in molecular and functional studies. Jan 2020. URL: https://doi.org/10.1111/cge.13698, doi:10.1111/cge.13698. This article has 32 citations and is from a peer-reviewed journal.

24. (chaves2023skewedxchromosomeinactivation pages 1-5): Luiza D. Chaves, Laura M. L. Carvalho, Giovanna C. Tolezano, Sara F. Pires, Silvia S. Costa, Marília O. de Scliar, Liane de R. Giuliani, Debora R. Bertola, Cíntia B. Santos-Rebouças, Go Hun Seo, Paulo A. Otto, Carla Rosenberg, Angela M. Vianna-Morgante, and Ana C. V. Krepischi. Skewed x-chromosome inactivation in women with idiopathic intellectual disability is indicative of pathogenic variants. Molecular Neurobiology, 60:3758-3769, Mar 2023. URL: https://doi.org/10.1007/s12035-023-03311-0, doi:10.1007/s12035-023-03311-0. This article has 11 citations and is from a peer-reviewed journal.

25. (khayat2019arecurrentmissense pages 45-45): Wujood Khayat, Anna Hackett, Marie Shaw, Alina Ilie, Tracy Dudding-Byth, Vera M Kalscheuer, Louise Christie, Mark A Corbett, Jane Juusola, Kathryn L Friend, Brian M Kirmse, Jozef Gecz, Michael Field, and John Orlowski. A recurrent missense variant in slc9a7 causes nonsyndromic x-linked intellectual disability with alteration of golgi acidification and aberrant glycosylation. Human Molecular Genetics, 28:598–614, Oct 2019. URL: https://doi.org/10.1093/hmg/ddy371, doi:10.1093/hmg/ddy371. This article has 45 citations and is from a domain leading peer-reviewed journal.

26. (neri2018x‐linkedintellectualdisability pages 1-3): Giovanni Neri, Charles E. Schwartz, Herbert A. Lubs, and Roger E. Stevenson. X‐linked intellectual disability update 2017. American Journal of Medical Genetics Part A, 176:1375-1388, Jun 2018. URL: https://doi.org/10.1002/ajmg.a.38710, doi:10.1002/ajmg.a.38710. This article has 154 citations.

Artifacts

• Edison artifact artifact-00